abstract |
The invention relates to biotechnology, immunology and virology. The claimed agent can be used for the prevention of diseases caused by severe acute respiratory syndrome virus SARS-CoV-2. The technical aim of the claimed group of inventions is to create agents containing a single active component and along with this ensuring the effective induction of immune response to the SARS-CoV-2 virus among broad strata of the population. Solution of the technical problem is a variant of the agent for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 in liquid form which contains, as a single active component, the expression vector based on the genome of the recombinant strain of human adenovirus serotype 26, wherein the El and E3 regions are deleted and the ORF6-Ad26 region is replaced by ORF6-Ad5, with an integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3. Also, there is created a variant of the agent for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 in liquid form which contains, as a single active component, the expression vector based on the genome of the recombinant strain of human adenovirus serotype 5, wherein the El and E3 regions are deleted, with an integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3. Further, there is claimed a variant of the agent for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 in liquid form which contains, as a single active component, the expression vector based on the genome of the recombinant strain of simian adenovirus serotype 25, wherein the El and E3 regions are deleted, with an integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:3. At that, for the particular case of implementation, a buffer solution of the agent for liquid form contains the following, mass%: tris from 0,1831 to 0,3432 sodium chloride from 0,3313 to 0,6212 sucrose from 3,7821 to 7,0915 magnesium chloride hexahydrate from 0,0154 to 0,0289 EDTA from 0,0029 to 0,0054 polysorbate-80 from 0,0378 to 0,0709 ethanol 95% from 0,0004 to 0,0007 water the remaining part. Each of the agent variants is used for inducing specific immunity against the severe acute respiratory syndrome SARS-CoV-2 virus. With that, the agent is intended for intranasal or intramuscular administration. Also, the agent can be administered concomitantly and simultaneously via intranasal and intramuscular routes. |